XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.

The secondary objectives are safety and pharmacokinetic interaction
Breast Neoplasms
DRUG: larotaxel (XRP9881)|DRUG: trastuzumab
Response rate (best overall response under treatment), study period
Incidence of grade 3-4 toxicities, pharmacokinetic interaction, study period
The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab.

The secondary objectives are safety and pharmacokinetic interaction